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he Pharmacogenetics
f Statin Therapy
hen the Body Aches,
he Mind Will Follow*
oseph S. Rossi, MD,
oward L. McLeod, PHARMD
hapel Hill, North Carolina
espite the increasing prevalence of cardiovascular risk
actors such as obesity, diabetes, and hyperlipidemia in the
.S., there has been a surprising decrease in cardiovascular
ortality among patients with various presentations of
oronary artery disease (1). It is likely, if not certain, that a
arge reason for this decline is the increased use of HMG-
oA reductase inhibitors to lower serum cholesterol and
romote stabilization of atherosclerotic plaque. Despite
igh levels of statin adherence in clinical trials, other studies
ave suggested poor adherence in high-risk patient popu-
ations, particularly the elderly (2,3). Although the safety
ata for this class of medications suggest a very low
ncidence of severe adverse reactions, such as rhabdomyol-
sis and myopathy, myalgias without serum creatine kinase
CK) elevation remain a common side effect and the most
ommon reason for discontinuation of therapy. Although
yalgia appears to be a class effect (it has been described
ith all available agents), there is a significant amount of
ariability within the class, which has lead to the investigation
f genetic determinants of statin metabolism and toxicity.
See page 1609
The safety of statin therapy has been vigorously debated
uring the last decade, and the balance of clinical trial data
as been reassuring. Cerivistatin was removed from the
arket after multiple cases of severe myopathy and rhab-
omyolysis, and this led to focused scrutiny of all other
vailable agents. Randomized trials involving tens of thou-
ands of patients have been performed demonstrating the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of North Carolina Schools of Medicine and Pharmacy,
arolina Center for Cardiovascular Biology, and the Institute for Pharmacogenomicsl
nd Individualized Therapy, University of North Carolina, Chapel Hill, North
arolina.afety and efficacy of simvastatin, atorvastatin, rosuvastatin,
ravastatin, fluvastatin, and lovastatin. Although each agent
as a unique pharmacology and drug interaction profile,
hen used as monotherapy for hyperlipidemia, there is a
ery low incidence of severe toxicity. In a meta-analysis of
5,000 patients treated with statin or placebo, there was no
ncreased risk of rhabdomyolysis among patients treated
ith statins (4). An analysis of 11 managed care plans
evealed only 24 cases of hospitalization for rhabdomyolysis
ver 252,000 patient-years (5). However, the use of high
oses of statins in combination with other drugs that alter
heir metabolism can lead to increasing blood levels with
onsequent risk of liver or muscle toxicity. This has been
emonstrated for virtually all available agents, but most
ommonly for agents metabolized by the CYP450 3A4
nzyme. Simvastatin in particular has been associated with
n increased risk of rhabdomyolysis when taken in combi-
ation with multiple inhibitors of CYP3A4 (6).
In this issue of the Journal, Voora et al. (7) report the
esults of the STRENGTH (Statin Response Examined by
enetic Haplotype Markers) study, and suggest that
educed-function single nucleotide polymorphisms (SNPs)
f the SLCO1B1 gene may be responsible for myopathy and
yalgia. SLCO1B1 encodes the enzyme OATP1B1, re-
ponsible for liver transportation of statins. This study was
nique because in addition to confirming the previously
uggested association between reduced function alleles for
his gene and CK elevation, they also confirmed an associ-
tion between the SLCO1B1*5 allele and myalgia symptoms
ithout CK elevation. Elevated levels of simvastatin metab-
lites (but not pravastatin) were seen among patients with
he targeted SNP. These exciting results demonstrate for
he first time that there may be a strong genetic suscepti-
ility to both myopathy and statin-induced myalgias in the
bsence of elevated serum CK, and that genetic testing may
rovide important prognostic information to guide individ-
alized statin therapy.
The SLCO1B1 gene has previously been identified as a
ikely factor in the development of simvastatin-induced
yopathy (8). In a genomewide study of approximately
00,000 markers among 85 subjects with confirmed myop-
thy from in the SEARCH (Study of the Effectiveness of
dditional Reductions in Cholesterol and Homocysteine)
tudy, the odds ratio for myopathy was 16.9 for patients
ith homozygous reduced-function SNPs at this locus. The
ole of SLCO1B1 in the metabolism of other statins remains
nclear. The STRENGTH study suggests that pravastatin
etabolites are not significantly elevated in patients with
he homozygous SLCO1B1 genotype. There was an increase
n the risk of myalgia among SNP carriers taking atorvasta-
in; however, the difference was not statistically significant.
o other agents were studied, and it is unknown whether
he same findings could be replicated for rosuvastatin,
ovasatin, and fluvastatin.
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Pharmacogenetics of Statin Therapy October 20, 2009:1617–8Despite these exciting findings and their clinical rele-
ance, they likely do not tell the whole story. Each individ-
al statin agent is dependent upon liver uptake for its
iologic effect; however, the dependence on transporter
roteins such as OATP1B1 vary according to agent. Li-
ophilic statins can enter the liver via passive diffusion,
hereas hydrophilic statins require active transportation.
luvastatin, for instance, has previously been shown to have
harmacokinetic properties that are independent of genetic
ariation at the SLCO1B1 locus (9). SLCO1B1 polymor-
hism has previously been shown to increase blood levels of
imvastatin acid (10). The search is on for additional genetic
ariants that may alter statin metabolism and cause adverse
vents.
The analysis by Voora et al. (7) also confirms a previous
ssociation between female sex and adverse events among
atients receiving statin therapy. Although the exact mech-
nism of this interaction is unknown, it is likely multifac-
orial. It is possible that female sex attenuates the activation
f metabolizing enzymes. It is also likely that lower mean
ody weight and muscle mass affects the volume of distri-
ution of some statin agents, making females more suscep-
ible to elevated circulating drug levels. These findings
uggest that lower doses of simvastatin should be considered
n female patients, and that changing agents is a reasonable
lternative in both males and females with likely statin-
nduced myalgias even in the absence of elevated serum CK.
Further studies will undoubtedly identify other genetic
actors associated with adverse reactions to statin agents. For
ow, the risk of severe reactions is fortunately rare and not
ikely to be improved by routine genetic testing. One of the
mportant issues that require additional investigation is the role
f SLCO1B1 in patients taking statin agents other than
imvastatin. The OATP1B1 enzyme is responsible for the
ransport of multiple statins, but it remains unclear whether the
enetic variants will have a similar effect on the incidence of
yalgias and myopathy. Voora et al. (7) found a nonsignificant
ncrease in myopathy among carriers of the SLCO1B1 alleles
mong patients taking atorvastatin, but found no increase in
yopathy among patients taking pravastatin. Previous research
ndicates that the enzyme encoded by SLCO1B1 affects sim-
astatin and pravastatin metabolism, but not fluvastatin (9,10).
he data by Voora et al. (7) suggest that simvastatin acid may
e a more clinically important substrate for this transporter
nzyme.
Genetic testing may someday become an important
djunct to risk stratification among patients with cardiovas-
ular disease. The prediction of adverse events based on
enetic variation is a focus of intense investigation for
tatins, ADP receptor antagonists, and warfarin. It seems
easonable, for now, to choose a statin based on known drug
nteractions, particularly CYP450 interactions, and goal
K
pow-density lipoprotein level. High doses should be reserved
or patients at intermediate to high risk of recurrent vascular
vents, and particular care should be taken to screen for
uscle symptoms among patients requiring high-dose ther-
py. If a patient develops myalgias or CK elevation while
aking simvastatin, a SNP at the SLCO1B1 locus should be
uspected, and changing agents may provide relief of symp-
oms. Further studies should examine the role of the
ATP1B1 enzyme in the transport and metabolism of
osuvastatin and atorvastatin, 2 of the most commonly
rescribed agents currently available. The elimination of
yalgias has the potential to dramatically improve statin
dherence and, therefore, clinical outcomes, and the vigi-
ance of investigators in the field supports our current level
f optimism that genetic testing will one day become an
mportant clinical tool.
eprint requests and correspondence: Dr. Howard L. McLeod,
niversity of North Carolina, Chapel Hill, Campus Box 7361,
enetic Medicine Building, Room 1094, Chapel Hill, North
arolina 27599. E-mail: hmcleod@unc.edu.
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